ABCA13 and erythema multiforme: Overall, this strategy allowed for the identification of 63 rare (MAF < 0.1%), predicted, and damaging variants within 21/46 genes and 3 novel candidates (ABCA13, NEB, and CSMD1) in 50/80 (63%) EM patients.